Comparative Pharmacology
Head-to-head clinical analysis: ALYQ versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYQ versus TZ 3.
ALYQ vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown